Susquehanna International Group, LLP Prelude Therapeutics Inc Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	BUY	$4.58 - $7.34 $166,666 - $267,102	36,390 Added 39.01%	129,680 $739,000
Q4 2022 Feb 14, 2023	BUY	$4.61 - $8.5 $367,412 - $677,441	79,699 Added 586.41%	93,290 $563,000
Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $79,185 - $139,682	-15,837 Reduced 53.82%	13,591 $90,000
Q2 2022 Aug 15, 2022	BUY	$4.0 - $7.55 $612 - $1,155	153 Added 0.52%	29,428 $154,000
Q4 2021 Feb 14, 2022	BUY	$11.89 - $31.74 $114,679 - $306,132	9,645 Added 49.13%	29,275 $364,000
Q3 2021 Nov 15, 2021	BUY	$25.78 - $38.65 $63,857 - $95,736	2,477 Added 14.44%	19,630 $613,000
Q2 2021 Aug 11, 2021	BUY	$28.63 - $44.3 $491,090 - $759,877	17,153 New	17,153 $491,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $34.6M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.